Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
News provided by
Share this article
Share this article
INDIANAPOLIS, May 19, 2021 /PRNewswire/ New data from across Eli Lilly and Company s (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021. The data include new analyses of Verzenio
® (abemaciclib) from the Phase 3 monarchE trial in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) with a high risk of recurrence who received neoadjuvant chemotherapy. In addition, the first clinical data from the Phase 1 study of Lilly s oral selective estrogen receptor degrader (SERD) will be presented at the meeting.
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
What are Neutrophil Extracellular Traps (NETs)?
The formation of neutrophil extracellular traps (NETs) from neutrophils can be induced by various microorganisms ranging from whole bacteria to fungi and protozoan parasites. In addition to their role in fighting infections, NETs have also emerged as a novel target for cancer therapy.
Image Credit: Kateryna Kon / Shutterstock.com
The role of neutrophils
As the most abundant leukocyte, which can also be referred to as white blood cells (WBC), present within the blood of human beings, neutrophils are the first line of defense against invading pathogens.
Neutrophils can employ several different mechanisms in their attack against microbes including phagocytosis, the generation of reactive oxygen species (ROS) and degranulation. Phagocytosis, for example, involves the engulfment and subsequent digestion of pathogens like bacteria or fungi by neutrophils.